Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 11 2015 Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results Aug 05 2015 Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results Jul 02 2015 First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder Jun 29 2015 Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis Jun 17 2015 Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference May 12 2015 Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results May 05 2015 Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results Apr 20 2015 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds Mar 24 2015 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results Mar 20 2015 Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015 Mar 17 2015 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2014 Financial Results Mar 04 2015 Cyclacel Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 03 2015 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Feb 03 2015 Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference Jan 06 2015 Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference Dec 16 2014 Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis Nov 11 2014 Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results Nov 04 2014 Cyclacel Pharmaceuticals to Release 2014 Third Quarter Financial Results Oct 09 2014 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML Sep 19 2014 Cyclacel to Present at BioCentury's Newsmakers in the Biotech Industry Conference Sep 18 2014 Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements Sep 11 2014 Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors Sep 10 2014 Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting Sep 02 2014 Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference Aug 12 2014 Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 11 2015 Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results Aug 05 2015 Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results Jul 02 2015 First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder Jun 29 2015 Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis Jun 17 2015 Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference May 12 2015 Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results May 05 2015 Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results Apr 20 2015 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds Mar 24 2015 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results Mar 20 2015 Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015 Mar 17 2015 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2014 Financial Results Mar 04 2015 Cyclacel Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 03 2015 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Feb 03 2015 Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference Jan 06 2015 Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference Dec 16 2014 Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis Nov 11 2014 Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results Nov 04 2014 Cyclacel Pharmaceuticals to Release 2014 Third Quarter Financial Results Oct 09 2014 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML Sep 19 2014 Cyclacel to Present at BioCentury's Newsmakers in the Biotech Industry Conference Sep 18 2014 Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements Sep 11 2014 Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors Sep 10 2014 Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting Sep 02 2014 Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference Aug 12 2014 Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
Jul 02 2015 First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Jun 29 2015 Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis
Apr 20 2015 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds
Mar 20 2015 Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015
Dec 16 2014 Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
Oct 09 2014 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML
Sep 18 2014 Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements
Sep 10 2014 Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting
Sep 02 2014 Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference
